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ABSTRACT
Iron overload and hepatitis virus C infection cause liver fibrosis in thalassemics. In a monocentric retrospective analysis of liver disease
in a cohort of 191 transfusion-dependent thalassemics, in 126 patients who had undergone liver biopsy (mean age 17.2 years; 58 hep-
atitis virus C-RNA positive and 68 hepatitis virus C-RNA negative) the liver iron concentration (median 2.4 mg/gr dry liver weight) was
closely related to serum ferritin levels (R = 0.58; p<0.0001). Male gender (OR 4.12) and serum hepatitis virus C-RNA positivity (OR
11.04) were independent risk factors for advanced liver fibrosis. The majority of hepatitis virus C-RNA negative patients with low iron load
did not develop liver fibrosis, while hepatitis virus C-RNA positive patients infected with genotype 1 or 4 and iron overload more frequent-
ly developed advanced fibrosis. Hepatitis virus C infection is the main risk factor for liver fibrosis in  transfusion-dependent thalassemics.
Adequate chelation therapy usually prevents the development of liver fibrosis in thalassemics free of hepatitis virus C-infection and
reduces the risk of developing severe fibrosis in thalassemics with chronic hepatitis C.
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Introduction
Thalassemics can develop liver fibrosis because of iron liver
overload1 and hepatitis virus C (HCV) infection.2 Multicenter
cross-sectional studies have reported that the development and
the severity of liver fibrosis are strongly related to the extent of
liver iron overload and to the presence of chronic HCV infec-
tion.3-7 Long-term observation of thalassemics who had under-
gone bone marrow transplantation showed that severe iron
overload and chronic HCV infection were independent risk fac-
tors for liver fibrosis progression.8 In the last 20 years, intensive
and adequate iron chelation therapy has reduced the iron over-
load in transfusion-dependent thalassemics,9 and the screening
of blood donors for HCV markers has minimized the risk of de
novo HCV infection.10
As a result, younger thalassemics should have a lower risk of
developing liver fibrosis, and the role of HCV infection should
be prominent in adult patients.    
We analyzed biochemical, virological and histological fea-
tures of a cohort of transfusion-dependent thalassemics who
had undergone chelation therapy and who had had a 15 year
follow-up.
Design and Methods
Patients
We performed a retrospective analysis of a prospective
cohort of 191 transfusion-dependent thalassemics followed
since 1990 at the Center for Thalassemia at the Paediatric
Hospital in Palermo, Italy. All patients underwent regular blood
transfusions maintaining pre-transfusion hemoglobin values at
9-9.5 g/dL and were treated with iron chelation therapy. The
children started deferoxamine at a dose of 20 mg/kg infused
subcutaneously 5–6 days per week, and  doses were increased
during infancy until reaching 40–60 mg/kg/day in adults.
Deferiprone was administrated at a dose of 75 mg/kg/day. The
iron chelation therapy was defined as adequate if the serum fer-
ritin values, checked every six months, were always lower than
2,500 ng/mL.11 Patients underwent splenectomy if the volume
of blood transfused was more than 250 mL/kg/year. The study
was performed in accordance with the principles of Good
Clinical Practice and was approved by the hospital’s Ethics
Committee. All adult patients, or parents of pediatric patients,
gave their consent to the collection of all clinical data in a data-
base. All patients were followed until December 2007 or death.
| 1244 | haematologica | 2008; 93(8)
Biochemical, virological and histological data
Serum ALT was measured at each transfusion, and
serum ferritin every six months. Anti-HCV antibodies
were tested by enzyme-immunoassay (EIA-2 and EIA-3
by Ortho Diagnostic Systems, Raritan, NJ, USA) at base-
line. Anti-HCV positive patients were tested for qualita-
tive serum HCV-RNA by polymerase chain reaction
(Amplicor HCV, Roche Molecular Systems, Basel,
Switzerland) at baseline, at the time of liver biopsy and
every year thereafter. HCV genotypes were determined
by a line probe assay (Innolipa, Innogenetics, Belgium).  
A liver biopsy was proposed to all patients who under-
went splenectomy, to all HCV-RNA positive patients
before the antiviral therapy with interferon, and to
patients who were to be switched to new iron chelation
drugs. We evaluated the first biopsy of each patient, and
none of the HCV-RNA positive patients were treated
with antiviral therapy before undergoing liver biopsy.
The degree of inflammation and the staging of fibrosis
were evaluated with the Scheuer score12 by a single
pathologist. The liver iron concentration (LIC) was
measured on fresh tissue cores that weighed more than
4 mg to reduce the variability of the measurement.13
Measurements were performed by atomic absorption
spectrometry using the Spectra 880 (Varian, Australia).
Results were expressed as mg of iron per gram of liver,
dry weight, and 1.8 mg/gr was considered the normal
limit. 
Statistical methods
All data were entered into a database and analyzed
using SPSS 13.0 for Windows software (SPSS Inc.,
Chicago, IL, USA). The differences between continuous
data were analyzed by parametric test (t-test) for vari-
ables with normal distribution, and by non-parametric
test (Mann-Whitney) for iron overload indices. χ2 analy-
sis was used for dichotomous or categorical variables.
Multiple logistic regression models were used to assess
the relationships between demographic data, biochemi-
cal features, virological characteristics, liver iron over-
load of the patients, and liver fibrosis. Variables found to
be significant on univariate analysis (p<0.05) were
included in multivariate logistic regression models. 
Results and Discussion
From 1990 we followed 191 transfusion-dependent
thalassemics (167 were born before 1990, and 24
between 1991 and 1998). Sixty patients (31.4%) were
anti-HCV negative, 63 patients (32.9%) were anti-HCV
positive but persistently HCV-RNA negative, and 68
patients (35.7%) had chronic active hepatitis C because
they were anti-HCV positive and persistently HCV-RNA
positive. One hundred and twenty-six patients under-
went liver biopsy during the 15 years of observation
(Figure 1). At the time of biopsy, the mean age of these
patients was 17.3 years; the median serum ferritin was
1,884 ng/mL, and 96 patients (76%) had values of serum
ferritin persistently lower than 2,500 ng/mL; 58 patients
(46%) were HCV-RNA positive, and 68  (54%) were
HCV-RNA negative. 
Liver iron concentration was measured on 100 avail-
able fresh tissue cores that weighed more than 4 mg (51
HCV-RNA negative patients, and 49 HCV-RNA positive
patients). Overall, median LIC was 2.4 mg/gr dry liver
weight (range 0.3-22 mg), 15 patients (14%) had LIC
values higher than 7 mg/gr and only 2 patients values
higher than 15 mg/gr dry liver weight. There were no
differences in LIC between intra-operative liver biopsy
performed during splenectomy and needle liver biopsy.
LIC was closely related to serum ferritin levels (R=0.58;
p<0.0001 95% CI 0.442-0.695). There were no signifi-
cant differences in iron overload between thalassemics
with and without HCV infection, as shown by median
values of serum ferritin and LIC, whereas HCV-RNA
positive patients had a higher mean age, higher serum
ALT levels, more severe liver inflammation, and more
frequently had severe liver fibrosis or cirrhosis (Table 1).
Male gender, high serum ALT values and HCV-RNA-
positivity, but not serum ferritin levels or LIC values,
were significantly associated with severe fibrosis or cir-
rhosis in univariate analysis (Table 2). Multivariate
analysis showed that male gender (Adjusted Odds Ratio
4.12; 95% CI 1.32-12.84) and serum HCV-RNA-positivi-
ty (Adjusted Odds Ratio 11.04; 95% CI 2.99-40.79) were
independent and significant risk factors for severe fibro-
sis or cirrhosis.  A sub-analysis of 68 HCV-RNA negative
patients showed that 21 out of 23 patients without liver
fibrosis, but only 19 out of 45 patients with each grade
of liver fibrosis, had serum ferritin values persistently
lower than 2,500 ng/mL (p=0.02). As regards LIC, 8 out
of 16 patients without liver fibrosis and 5 out of 35
patients with each grade of liver fibrosis had values
lower than 1.8 mg/gr dry liver weight (p=0.01).  The
mean age of HCV-RNA negative patients without iron
overload was 16.6 years. The 3 HCV-RNA negative
patients with severe fibrosis or cirrhosis had a median
LIC of 4.9 mg/gr dry liver weight, and a mean age of 14.3
years.  Among HCV-RNA positive patients, 34 out of 39
with absent, mild or moderate fibrosis had serum ferritin
values persistently lower than 2,500 ng/mL compared to
12 out of 19 patients with severe fibrosis or cirrhosis
(p=0.04). As regards the liver iron concentration of this
group of patients, 19 out of 32 with absent, mild or mod-
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Figure 1. Flow chart of patients followed in the center, patients
with and without hepatitis virus C infection, and patients who did
or did not undergo liver biopsy.
191 transfusion-dependent thalassemics followed from 1990
123 HCV-RNA negative patients
(64.4%)
• 68 patients (55.2%) who underwent 
liver biopsy
• 55 patients (44.8%) did not undergo liver biopsy • 10 patients (14.7) did not undergo liver 
biopsy
• 58 patients (85.3%) who underwent 
liver biopsy
• 42 at time of splenectomy
• 26 before switching to oral therapy
with deferiprone
• 8 died of heart disease or other 
complications
• 8 underwent bone marrow transplant
• 31 had normal ALT values and
ferritin levels <2,500 ng/mL
• 8 refused to undergo liver biopsy
• 5 at time of splenectomy
• 53 before the start of antiviral therapy
• 5 died of heart disease or other 
complications
• 1 died of hepatocellular carcinoma
• 4 refused to undergo liver biopsy
68 HCV-RNA positive patients
(35.6%)
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erate fibrosis versus 4 out of 13 with severe fibrosis or
cirrhosis had values lower than 1.8 mg/gr dry liver
weight (p=0.03). The median LIC in HCV-RNA positive
patients with severe fibrosis or cirrhosis was 2.9 mg/gr
dry liver weight.  Finally, among patients with HCV hep-
atitis, infection with genotypes 1 or 4 was significantly
associated with severe fibrosis or cirrhosis compared to
genotypes 2 or 3 (19/49 vs. 0/9; p=0.02). Most adult tha-
lassemics present iron overload and HCV infection,
while young subjects, born in the era of regular transfu-
sion regimens and intensive chelation therapy, have a
mild iron overload and are frequently free of HCV infec-
tion. Several published studies have reported that the
progression of liver fibrosis is strongly related to the
extent of iron overload and to the presence of chronic
HCV infection. Retrospective or cross-sectional datasets
have shown some limitations and bias, including the
high number of centers that selected patients in multi-
center studies3,5 or the low number of patients who
underwent liver biopsies in the studies performed in sin-
gle centers,4,6,7 the selection of patients with biochemical
and virological features of chronic hepatitis C5 or with
high iron overload,14 the measurement of LIC by differ-
ent laboratories5,8 and the analysis of liver biopsy by sev-
eral pathologists.3 We evaluated liver damage in a cohort
of 191 transfusion-dependent thalassemics treated with
blood transfusion and adequate iron chelation drugs.
The majority of thalassemics transfused before 1990
were infected by HCV in the first years of life. In fact, at
baseline 131 patients (68%) were positive for anti-HCV
antibodies, but only half of them had active chronic
HCV infection, as shown by persistence of serum HCV-
RNA. Patients with chronic hepatitis C were older, had
higher ALT values and degrees of inflammation, and
more frequently had a severe liver fibrosis or cirrhosis,
while there were no differences in iron overload
between the two groups, as shown by values of serum
ferritin and LIC. The mean value of serum ferritin in all
patients who underwent liver biopsy was lower than
2,000 ng/mL and the median value of LIC in 100 patients
with adequate fresh tissue specimens was 2.4 mg/gr dry
liver weight. 
The indices of iron overload observed in our cohort
were lower than those reported in other studies.5-8 The
high number of patients with values of serum ferritin
persistently lower than 2,500 ng/mL suggests an ade-
quate iron chelation treatment and good adherence to
therapy. Some published studies have reported median
values of serum ferritin lower than 2,000 ng/mL, but a
median LIC higher than 6 mg/gr dry liver weight.3,5,6
These data could be related to the methods used to
measure LIC. We measured LIC in a single laboratory
using the same method for the entire period of observa-
tion and used only fresh tissue cores that weighed more
than 4 mg in order to reduce the variability of the results.
The analysis showed no differences between LIC meas-
ured on liver biopsy performed during splenectomy and
needle biopsy, and LIC was closely related to serum fer-
ritin levels, as reported in other studies.3,7
The separate analysis of the HCV-RNA-negative
group showed that one third of the patients had no liver
fibrosis and that the majority of them had values of
serum ferritin lower than 2,500 mg/dL and LIC lower
than 1.8 mg/gr dry liver weight. The median LIC value
in 3 HCV-RNA negative patients with severe fibrosis or
cirrhosis was 4.9 mg/gr dry liver weight.  There was no
difference regarding age between HCV-RNA negative
patients with or without liver fibrosis.  These data con-
firm that patients free of HCV infection with a good
adherence to chelation therapy usually do not develop
liver fibrosis, and that only values higher than 5 mg/gr
dry liver weight are associated with severe fibrosis.8
HCV-RNA-positive patients had higher serum ALT lev-
els, more severe liver inflammation and more frequently
had severe liver fibrosis or cirrhosis. Multivariate analy-
sis showed that male gender and serum HCV-RNA pos-
itivity were independent and significant risk factors for
severe fibrosis or cirrhosis.  Several studies suggest that
HCV infection acquired early in life shows a slow pro-
Iron overload and hepatitis C virus in thalassemia major
Table 1. Clinical, biochemical, virological and histological features
of 126 patients who underwent liver biopsy.
HCV-RNA negative HCV-RNA positive p
(68 patients) (58 patients)
Age (mean,SD) 13.9±(8.85) 21.2± (8.87) <0.001
Gender (M/F) 35/33 32/26 0.681
ALT (median, range) 27 (9-200) 82 (17-547) <0.001
Ferritin (median, range) 1,892 (141-5,952) 1,750 (188- 5,503) 0.590
LIC (median, range) 3.3 (0.3-22) 2.3 (0.4-11.8) 0.064
Histological inflammation (grading)        
Absent 23 (34%) 0
Mild/moderate 45 (66%) 56 (96%) <0.001
Severe 0 2 (4%)
Histological fibrosis 
Absent 23 (34%) 2 (4%)
Mild/moderate 42 (62%) 37 (64%) <0.001
Severe/cirrhosis 3 (4%) 19 (32%)
Scheuer score (12). Histological inflammation (grading):  absent (grade 0), mild
(grade 1), moderate (grade 2), severe (grade 3). Histological fibrosis (staging): no
fibrosis (stage 0), periportal fibrosis (stage 1), porto-portal septa (stage 2),  porto-
central septa (stage 3), cirrhosis (stage 4).  
Table 2. Univariate analysis of biochemical, virological and histo-
logical features associated with severe fibrosis (Stage 3 and 4 by
Scheuer score) versus milder or no fibrosis (Stages 0-2) in 126
patients who underwent liver biopsy.
Fibrosis stage Fibrosis stage p
0-1-2 3- 4
(104 patients) (22 patients)
Age (mean,SD) 16.8±8.7 19.7±9.2 0.2
Gender (M/F) 50/54 17/5 0.01
ALT (mean, SD) 69.1±80.1 112.5±61.2 < 0.001
Ferritin (median, range) 1,583 (141-5,952) 2,115 (188- 5,503) 0.3
HCV-RNA positive 39 (37.5%) 19 (86.4%) < 0.001
LIC (median, range) 2.3 (0.3-22) 2.9 (0.4-11.8) 0.3
Histological inflammation (grading)        
Grade 0 23 (22%) 0
Grade 1/Grade 2 79 (76%) 22 (100%)
Grade 3 2 (2%) 0 0.2
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gression during the first 20 - 30 years of life,15-17 but other
studies report that despite a young age at the time of
HCV infection, the progression of liver disease in chil-
dren is comparable to that seen in adults.18 Among our
58 patients with active chronic hepatitis C, 14 patients
(24%) had cirrhosis. Patients with mild or moderate
fibrosis frequently had low values of serum ferritin and
normal LIC, while patients with severe liver fibrosis or
cirrhosis more frequently had values of serum ferritin
higher than 2,500 ng/mL and a median LIC value 2.9
mg/gr dry liver weight. These findings confirm that
HCV-RNA-positive patients with normal liver iron con-
centration usually do not develop severe liver fibrosis
during the first 20-30 years of life, whereas patients with
active HCV replication and moderate iron overload more
frequently develop severe fibrosis or cirrhosis.8 Finally,
in thalassemics with active HCV infection, another
determinant of liver disease progression may be infec-
tion with genotypes 1 or 4, as reported in a long-term
observational cohort of adult subjects with chronic hep-
atitis C.19
In conclusion, HCV infection is the main risk factor for
liver fibrosis  in  transfusion-dependent thalassemics and
infection with genotypes 1 or 4 increases the risk of
developing severe fibrosis. Adherence to adequate chela-
tion therapy usually prevents the development of liver
fibrosis in thalassemics free of HCV-infection and
reduces the risks of developing severe fibrosis in tha-
lassemics with chronic hepatitis C. 
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